Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q4 FY2025 Earnings Presentation
9 slides from Orchid Pharma's earnings presentation, May 26, 2025
Slide 1: Cover letter to NSE and BSE: Investors Presentation Q4 FY2025
May 26, 2025 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listi
Slide 2: Financials Q4 & FY-25
Orchid Pharma Limited Financials Q4 & FY-25 • All results in Standalone basis. • These are approx. nos. for exact nos. pls refer financials.
Slide 3: Financial Highlights QTR-4 FY-25
Financial Highlights QTR-4 FY-25 +9% +13% -2% +11% -7% +15% -15% +12%
Slide 4: Financial Performance Including AMS
Financial Performance Including AMS (Amt. in Cr.) Q4-25 Q4-24 Change % FY-25 FY-24 Change % Sales 237 217 9% 922 819 13% Other Income 6 13 -54% 32 30 7% COGS 138 128 8% 544 484 12% Employee Exp 22 18 22% 86 70 23% Other Exp 43 43 0% 168 155 8% EBITDA* 40 41 -2% 156 140 11% % to Sales 17% 19% 17% 17%
Slide 5: Turnover (Amt. in Cr.)
Turnover (Amt. in Cr.) 1,000 922 900 819 800 700 666 600 557 500 451 400 300 200 100 - FY-21 FY-22 FY-23 FY-24 FY-25
Slide 6: EBIDTA, PBT & PAT as % to Sales FY-25
EBIDTA, PBT & PAT as % to Sales FY-25 20% 17% 17% 14% 15% 15% 12% 12% 11% 11% 11% 10% 5% 2% 2% 0% -5% -9% -9% -10% -15% -21% -20% -21% -25% FY-21 FY-22 FY-23 FY-24 FY-25 EBITDA 14% 12% 15% 17% 17% PBT -21% -9% 2% 11% 11% PAT -21% -9% 2% 12% 11% EBITDA PBT PAT
Slide 7: P&L Analysis – Gross Margin % to Sales
P&L Analysis – Gross Margin % to Sales Gross Margin Yearly Basis 60% 49% 50% 44% 42% 41% 41% 40% 30% 20% 10% 0% FY-21 FY-22 FY-23 FY-24 FY-25
Slide 8: P&L Analysis – Exp. % to Sales 12M
P&L Analysis – Exp. % to Sales 12M 25% 22% 23% 20% 20% 19% 18% 15% 14% 11% 10% 9% 10% 8% 5% 0% FY-21 FY-22 FY-23 FY-24 FY-25 Emp Benefit Other Exp
Slide 9: Thank You
Thank You